Targovax ASA – OSE:TRVX.OL
Targovax ASA stock price today
Targovax ASA stock price monthly change
Targovax ASA stock price quarterly change
Targovax ASA stock price yearly change
Targovax ASA key metrics
Market Cap | 123.47M |
Enterprise value | 94.32M |
P/E | -1.03 |
EV/Sales | N/A |
EV/EBITDA | -0.92 |
Price/Sales | N/A |
Price/Book | 0.37 |
PEG ratio | 0.09 |
EPS | -2.29 |
Revenue | N/A |
EBITDA | -97.66M |
Income | -432.9M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTargovax ASA stock price history
Targovax ASA stock forecast
Targovax ASA financial statements
| Mar 2022 | 0 | -30.43M | |
|---|---|---|---|
| Jun 2022 | 0 | -29.16M | |
| Sep 2022 | 0 | -20.73M | |
| Dec 2022 | 10.00M | -352.56M | -3524.95% |
| Mar 2022 | 524251000 | 142.05M | 27.1% |
|---|---|---|---|
| Jun 2022 | 524284000 | 152.92M | 29.17% |
| Sep 2022 | 507389000 | 149.05M | 29.38% |
| Dec 2022 | 100414000 | 97.84M | 97.44% |
| Mar 2022 | -31.03M | -1K | -609K |
|---|---|---|---|
| Jun 2022 | -26.70M | 1K | -371K |
| Sep 2022 | -27.45M | 0 | -2.68M |
| Dec 2022 | -23.63M | -4.95M | -663K |
Targovax ASA alternative data
| Aug 2023 | 20 |
|---|---|
| Sep 2023 | 20 |
| Oct 2023 | 20 |
| Nov 2023 | 20 |
| Dec 2023 | 20 |
| Jan 2024 | 20 |
| Feb 2024 | 20 |
| Mar 2024 | 20 |
| Apr 2024 | 20 |
| May 2024 | 20 |
| Jun 2024 | 20 |
| Jul 2024 | 20 |
Targovax ASA other data
| Patent |
|---|
Application ONCOLYTIC ADENOVIRAL VECTOR EXPRESSING PEPTIDYLARGININE DEIMINASE AND TISSUE INHIBITOR OF METALLOPROTEINASE Filling date: 16 Apr 2020 Issue date: 19 May 2022 |
Grant Utility: Peptide mixture Filling date: 27 Sep 2017 Issue date: 24 Mar 2020 |
Application Filling date: 16 Jun 2016 Issue date: 12 Dec 2019 |
Grant Utility: Peptide mixture Filling date: 2 Aug 2017 Issue date: 29 Oct 2019 |
| Insider | Compensation |
|---|---|
Mr. Øystein Soug M.Sc (1969) Special Advisor & Interim Chief Financial Officer | $3,650,000 |
-
What's the price of Targovax ASA stock today?
One share of Targovax ASA stock can currently be purchased for approximately $2.17.
-
When is Targovax ASA's next earnings date?
Unfortunately, Targovax ASA's (TRVX.OL) next earnings date is currently unknown.
-
Does Targovax ASA pay dividends?
No, Targovax ASA does not pay dividends.
-
How much money does Targovax ASA make?
Targovax ASA has a market capitalization of 123.47M.
-
What is Targovax ASA's stock symbol?
Targovax ASA is traded on the OSE under the ticker symbol "TRVX.OL".
-
What is Targovax ASA's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Targovax ASA?
Shares of Targovax ASA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Targovax ASA's key executives?
Targovax ASA's management team includes the following people:
- Mr. Øystein Soug M.Sc Special Advisor & Interim Chief Financial Officer(age: 56, pay: $3,650,000)
-
How many employees does Targovax ASA have?
As Jul 2024, Targovax ASA employs 20 workers.
-
When Targovax ASA went public?
Targovax ASA is publicly traded company for more then 9 years since IPO on 8 Jul 2016.
-
What is Targovax ASA's official website?
The official website for Targovax ASA is targovax.com.
-
How can i contact Targovax ASA?
Targovax ASA can be reached via phone at +47 21 39 88 10.
Targovax ASA company profile:
Targovax ASA
targovax.comOSE
20
Biotechnology
Healthcare
Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.
Lysaker, 1366
:
ISIN: NO0010689326
:
